Korean Journal of Radiology

  • 제11권3호
  • /
  • Pages.304-311
  • /
  • 2010
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Quantitative Assessment of the T2 Relaxation Time of the Gluteus Muscles in Children with Duchenne Muscular Dystrophy: a Comparative Study Before and After Steroid Treatment

  • Kim, Hee-Kyung (Department of Radiology, Cincinnati Children's Hospital Medical Center) ;
  • Laor, Tal (Department of Radiology, Cincinnati Children's Hospital Medical Center) ;
  • Horn, Paul S. (Department of Mathematical Sciences, University of Cincinnati) ;
  • Wong, Brenda (Department of Neurology, Cincinnati Children's Hospital Medical Center)
  • 투고 : 2009.09.29
  • 심사 : 2010.01.25
  • 발행 : 2010.06.01
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To determine the feasibility of using T2 mapping as a quantitative method to longitudinally follow the disease activity in children with Duchenne muscular dystrophy (DMD) who are treated with steroids. Materials and Methods: Eleven boys with DMD (age range: 5-14 years) underwent evaluation with the clinical functional score (CFS), and conventional pelvic MRI and T2 mapping before and during steroid therapy. The gluteus muscle inflammation and fatty infiltration were evaluated on conventional MRI. The histograms and mean T2 relaxation times were obtained from the T2 maps. The CFS, the conventional MRI findings and the T2 values were compared before and during steroid therapy. Results: None of the patients showed interval change of their CFSs. On conventional MRI, none of the images showed muscle inflammation. During steroid treatment, two boys showed increased fatty infiltration on conventional MRI, and both had an increase of the mean T2 relaxation time (p < 0.05). The remaining nine boys had no increase in fatty infiltration. Of these, three showed an increased mean T2 relaxation time (p < 0.05), two showed no change and four showed a decreased mean T2 relaxation time (p < 0.05). Conclusion: T2 mapping is a feasible technique to evaluate the longitudinal muscle changes in those children who receive steroid therapy for DMD. The differences of the mean T2 relaxation time may reflect alterations in disease activity, and even when the conventional MRI and CFS remain stable.

키워드

참고문헌

  1. Sarnat HB. Neuromuscular disorder. In: Kliegman R, ed. Nelson textbook of pediatrics. Philadelphia: Saunders, 2007:1680-1696
  2. Strober JB. Therapeutics in duchenne muscular dystrophy. NeuroRx 2006;3:225-234 https://doi.org/10.1016/j.nurx.2006.01.005
  3. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005;65:826-834 https://doi.org/10.1212/01.wnl.0000173836.09176.c4
  4. Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology 1991;41:661-666 https://doi.org/10.1212/WNL.41.5.661
  5. Swinyard CA, Deaver GG, Greenspan L. Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases. Arch Phys Med Rehabil 1957;38:574-579
  6. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103 https://doi.org/10.1002/mus.880060204
  7. Sookhoo S, Mackinnon I, Bushby K, Chinnery PF, Birchall D. MRI for the demonstration of subclinical muscle involvement in muscular dystrophy. Clin Radiol 2007;62:160-165 https://doi.org/10.1016/j.crad.2006.08.012
  8. Stern LM, Caudrey DJ, Perrett LV, Boldt DW. Progression of muscular dystrophy assessed by computed tomography. Dev Med Child Neurol 1984;26:569-573
  9. Liu GC, Jong YJ, Chiang CH, Jaw TS. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology 1993;186:475-480 https://doi.org/10.1148/radiology.186.2.8421754
  10. Kight AC, Dardzinski BJ, Laor T, Graham TB. Magnetic resonance imaging evaluation of the effects of juvenile rheumatoid arthritis on distal femoral weight-bearing cartilage. Arthritis Rheum 2004;50:901-905 https://doi.org/10.1002/art.20062
  11. Dunn TC, Lu Y, Jin H, Ries MD, Majumdar S. T2 relaxation time of cartilage at MR imaging: comparison with severity of knee osteoarthritis. Radiology 2004;232:592-598 https://doi.org/10.1148/radiol.2322030976
  12. Huang Y, Majumdar S, Genant HK, Chan WP, Sharma KR, Yu P, et al. Quantitative MR relaxometry study of muscle composition and function in Duchenne muscular dystrophy. J Magn Reson Imaging 1994;4:59-64 https://doi.org/10.1002/jmri.1880040113
  13. Maillard SM, Jones R, Owens C, Pilkington C, Woo P, Wedderburn LR, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004;43:603-608 https://doi.org/10.1093/rheumatology/keh130
  14. Patten C, Meyer RA, Fleckenstein JL. T2 mapping of muscle. Semin Musculoskelet Radiol 2003;7:297-305 https://doi.org/10.1055/s-2004-815677
  15. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007;25:433-440
  16. Muntoni F, Fisher I, Morgan JE, Abraham D. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscul Disord 2002;12:S162-S165 https://doi.org/10.1016/S0960-8966(02)00101-3
  17. Weller B, Massa R, Karpati G, Carpenter S. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 1991;14:771-774 https://doi.org/10.1002/mus.880140812
  18. Davies KE. Challenges in Duchenne muscular dystrophy. Neuromuscul Disord 1997;7:482-486 https://doi.org/10.1016/S0960-8966(97)00107-7
  19. Kissel JT, Burrow KL, Rammohan KW, Mendell JR. Mononuclear cell analysis of muscle biopsies in prednisonetreated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology 1991;41:667-672 https://doi.org/10.1212/WNL.41.5.667
  20. Phoenix J, Betal D, Roberts N, Helliwell TR, Edwards RH. Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Muscle Nerve 1996;19:302-310 https://doi.org/10.1002/(SICI)1097-4598(199603)19:3<302::AID-MUS4>3.0.CO;2-H
  21. DeSilva S, Drachman DB, Mellits D, Kuncl RW. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol 1987;44:818-822 https://doi.org/10.1001/archneur.1987.00520200022012
  22. Bonifati DM, Witchel SF, Ermani M, Hoffman EP, Angelini C, Pegoraro E. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry 2006;77:1177-1179 https://doi.org/10.1136/jnnp.2005.078345

피인용 문헌

  1. Diffusion tensor MRI to assess skeletal muscle disruption following eccentric exercise vol.46, pp.1, 2010, https://doi.org/10.1002/mus.23276
  2. Skeletal Muscle Edema in Muscular Dystrophy: Clinical and Diagnostic Implications vol.23, pp.1, 2012, https://doi.org/10.1016/j.pmr.2011.11.016
  3. Quantitative MRI can detect subclinical disease progression in muscular dystrophy vol.259, pp.8, 2010, https://doi.org/10.1007/s00415-011-6393-2
  4. T2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross‐sectional study of lower leg muscles in 5–15‐year vol.26, pp.3, 2010, https://doi.org/10.1002/nbm.2851
  5. Neuromuscular imaging in muscular dystrophies and other muscle diseases vol.5, pp.3, 2013, https://doi.org/10.2217/iim.13.26
  6. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy vol.260, pp.4, 2013, https://doi.org/10.1007/s00415-012-6733-x
  7. Analysis of fatty infiltration and inflammation of the pelvic and thigh muscles in boys with Duchenne muscular dystrophy (DMD): grading of disease involvement on MR imaging and correlation with clinic vol.43, pp.10, 2010, https://doi.org/10.1007/s00247-013-2696-z
  8. Reply to Drs. Azzabou and Carlie regarding objective measurement of minimal fat in normal skeletal muscles of healthy children using T2 relaxation time mapping (T2 maps) and MR spectroscopy vol.44, pp.12, 2014, https://doi.org/10.1007/s00247-014-3177-8
  9. Objective measurement of minimal fat in normal skeletal muscles of healthy children using T2 relaxation time mapping (T2 maps) and MR spectroscopy vol.44, pp.2, 2010, https://doi.org/10.1007/s00247-013-2791-1
  10. Chemical shift‐based MRI to measure fat fractions in dystrophic skeletal muscle vol.72, pp.1, 2010, https://doi.org/10.1002/mrm.24917
  11. Update in Pediatric Imaging vol.61, pp.1, 2014, https://doi.org/10.1016/j.yapd.2014.03.010
  12. Effectiveness of diffusion tensor imaging in assessing disease severity in Duchenne muscular dystrophy: preliminary study vol.45, pp.4, 2010, https://doi.org/10.1007/s00247-014-3187-6
  13. Diffusion tensor imaging and T2 mapping in early denervated skeletal muscle in rats vol.42, pp.3, 2010, https://doi.org/10.1002/jmri.24818
  14. Assessment OF aged mdx mice by electrical impedance myography and magnetic resonance imaging vol.52, pp.4, 2015, https://doi.org/10.1002/mus.24573
  15. Impact of a Comparative Study on the Management of Scoliosis in Duchenne Muscular Dystrophy: Are Corticosteroids Decreasing the Rate of Scoliosis Surgery in the United States? vol.41, pp.17, 2010, https://doi.org/10.1097/brs.0000000000001534
  16. T2 relaxation times are increased in Skeletal muscle of DMD but not BMD patients vol.53, pp.1, 2010, https://doi.org/10.1002/mus.24679
  17. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study vol.15, pp.1, 2010, https://doi.org/10.1016/s1474-4422(15)00242-2
  18. Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy vol.3, pp.8, 2010, https://doi.org/10.1002/acn3.319
  19. Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy vol.264, pp.1, 2010, https://doi.org/10.1007/s00415-016-8311-0
  20. Elevated phosphodiester and T2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients vol.30, pp.1, 2010, https://doi.org/10.1002/nbm.3667
  21. Esophageal carcinoma: Ex vivo evaluation by high‐spatial‐resolution T2‐mapping MRI compared with histopathological findings at 3.0T vol.45, pp.6, 2017, https://doi.org/10.1002/jmri.25509
  22. Diffusion tensor imaging of the human calf: Variation of inter‐ and intramuscle‐specific diffusion parameters vol.46, pp.4, 2010, https://doi.org/10.1002/jmri.25650
  23. Advances in Quantitative Imaging of Genetic and Acquired Myopathies: Clinical Applications and Perspectives vol.10, pp.None, 2010, https://doi.org/10.3389/fneur.2019.00078
  24. T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy vol.39, pp.1, 2010, https://doi.org/10.1007/s11596-019-2012-8
  25. Dynamic contrast-enhanced magnetic resonance imaging in denervated skeletal muscle: Experimental study in rabbits vol.14, pp.4, 2010, https://doi.org/10.1371/journal.pone.0215069
  26. Patellofemoral Instability in Children: Correlation Between Patellofemoral Incongruence, Mechanism of Injury, and Cartilage Damage vol.213, pp.1, 2010, https://doi.org/10.2214/ajr.18.20778
  27. Validation of SE-EPI-based T2 mapping for characterization of prostate cancer: a new method compared with the traditional CPMG method vol.44, pp.10, 2010, https://doi.org/10.1007/s00261-019-02105-0
  28. MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy vol.88, pp.4, 2010, https://doi.org/10.1002/ana.25804